# Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct05669599` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05669599](<https://clinicaltrials.gov/study/NCT05669599>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05669599

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 592 participants.

## Technical summary

Registry record NCT05669599. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-18 (actual); primary completion 2024-10-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 592 participants (enrolled count; ClinicalTrials.gov record NCT05669599, source copy `cardio:ctgov-nct05669599-2026-01-20`, retrieved 2026-10-26)
- Started: 2023-01-18 (actual) (ClinicalTrials.gov record NCT05669599, source copy `cardio:ctgov-nct05669599-2026-01-20`, retrieved 2026-10-26)
- Primary completion: 2024-10-08 (actual) (ClinicalTrials.gov record NCT05669599, source copy `cardio:ctgov-nct05669599-2026-01-20`, retrieved 2026-10-26)
- Completion: 2025-12-16 (actual) (ClinicalTrials.gov record NCT05669599, source copy `cardio:ctgov-nct05669599-2026-01-20`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Czechia; Germany; Hong Kong SAR China; Hungary; Japan; Poland; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT05669599, source copy `cardio:ctgov-nct05669599-2026-01-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05669599-2026-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
- Condition: Obesity
- Condition: Overweight
- Condition: Type 2 Diabetes Mellitus
- Intervention (Biological): Maridebart Cafraglutide
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: a7f19f95aa5c61359e61b37d36b7f09679209da2a9fb595c55e1e925e636f5c0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
